| Old Articles: <Older 1521-1530 Newer> |
|---|
 |
The Motley Fool
November 10, 2004
Rich Smith |
Natus Delivers Infant care equipment maker proves true to its word. For the year to come, Natus expects revenues of from $41 million to $43 million to translate into diluted per-share profits of $0.26 to $0.28.   |
The Motley Fool
November 9, 2004
Charly Travers |
Genta's on the Ropes Aventis' exit leaves the pharmaceutical company in dire straits. Genta's stock opened down 40% this morning and is now down 85% for the year. |
The Motley Fool
November 9, 2004
Rich Smith |
Eyeing Laser Care Profits Eye care specialist TLC draws eyes to the field of high-tech vision correction. The company swung to a $0.05-per-diluted-share profit against its year-ago $0.06 loss. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
November 8, 2004
Charly Travers |
A Fantastic Cancer-Drug Deal Has Medarex hit the jackpot with MDX-010? Aside from the great financial terms, this deal is an important step in Medarex's transition from a research company to a company with commercial operations. |
The Motley Fool
November 8, 2004
Brian Gorman |
Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
The Motley Fool
November 5, 2004
Phil Wohl |
WebMD Needs a Shot The online provider of health-care information shares have declined more than 5% today to a price of $7.22 per share. The company appears to be putting a bandage on its problems instead of fully treating the issues. |
The Motley Fool
November 4, 2004
Tim Beyers |
One Quality Stock A great earnings report reveals more opportunity for investors in Quality Systems, a company that helps smaller medical practices update and manage record keeping with custom hardware and software. |
The Motley Fool
November 4, 2004
Charly Travers |
Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important. |
| <Older 1521-1530 Newer> Return to current articles. |
